Lilly's Diabetic Neuropathy Agent Ruboxistaurin Will Be Called Arxxant
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is proposing to market the diabetic peripheral neuropathy agent ruboxistaurin under the trade name Arxxant
You may also be interested in...
Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials
Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.